NO2563385T3 - - Google Patents

Info

Publication number
NO2563385T3
NO2563385T3 NO11778000A NO11778000A NO2563385T3 NO 2563385 T3 NO2563385 T3 NO 2563385T3 NO 11778000 A NO11778000 A NO 11778000A NO 11778000 A NO11778000 A NO 11778000A NO 2563385 T3 NO2563385 T3 NO 2563385T3
Authority
NO
Norway
Application number
NO11778000A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2563385T3 publication Critical patent/NO2563385T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO11778000A 2010-04-28 2011-04-28 NO2563385T3 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32907810P 2010-04-28 2010-04-28
PCT/US2011/034282 WO2011139820A1 (en) 2010-04-28 2011-04-28 Methods of use of soluble cd24 for therapy of rheumatoid arthritis

Publications (1)

Publication Number Publication Date
NO2563385T3 true NO2563385T3 (cg-RX-API-DMAC7.html) 2017-12-30

Family

ID=44903987

Family Applications (1)

Application Number Title Priority Date Filing Date
NO11778000A NO2563385T3 (cg-RX-API-DMAC7.html) 2010-04-28 2011-04-28

Country Status (17)

Country Link
US (1) US8808697B2 (cg-RX-API-DMAC7.html)
EP (3) EP2563385B1 (cg-RX-API-DMAC7.html)
JP (5) JP5899206B2 (cg-RX-API-DMAC7.html)
KR (1) KR20130086126A (cg-RX-API-DMAC7.html)
CN (2) CN105381451B (cg-RX-API-DMAC7.html)
AU (1) AU2011248540B2 (cg-RX-API-DMAC7.html)
CA (1) CA2795823C (cg-RX-API-DMAC7.html)
DK (1) DK2563385T3 (cg-RX-API-DMAC7.html)
EA (2) EA027735B1 (cg-RX-API-DMAC7.html)
ES (2) ES2645262T3 (cg-RX-API-DMAC7.html)
IL (1) IL222739A0 (cg-RX-API-DMAC7.html)
NO (1) NO2563385T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ603196A (cg-RX-API-DMAC7.html)
PL (2) PL3260128T3 (cg-RX-API-DMAC7.html)
PT (2) PT3260128T (cg-RX-API-DMAC7.html)
SG (1) SG184907A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011139820A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
CN107531772B (zh) * 2015-05-07 2021-09-21 肿瘤免疫股份有限公司 Cd24用于降低低密度脂蛋白胆固醇水平的用途
SG11201806338SA (en) * 2016-02-02 2018-08-30 Oncoimmune Inc Use of cd24 proteins for treating leptin-deficient conditions
US10758574B2 (en) 2016-04-28 2020-09-01 The Board Of Trustees Of The Leland Stanford Junior University Cartilage cells with a high regenerative potential and low immune response for use in cellular therapy
KR101789449B1 (ko) * 2016-12-08 2017-10-23 박문수 폐유지를 이용한 지방산 메틸에스테르 제조방법
CN110461353A (zh) * 2017-03-07 2019-11-15 肿瘤免疫股份有限公司 可溶性cd24用于治疗系统性红斑狼疮的使用方法
KR20200034957A (ko) * 2017-05-15 2020-04-01 온코이뮨, 아이앤씨. 신경 보호 및 재수초화를 위한 가용성 cd24의 사용 방법
CN110799206A (zh) * 2017-05-22 2020-02-14 肿瘤免疫股份有限公司 使用可溶性cd24治疗癌症疗法中免疫相关不良事件的方法
AU2019231191A1 (en) * 2018-03-05 2020-09-03 Institute Of Biophysics, Chinese Academy Of Sciences Methods of use of soluble CD24 for treating acquired immune deficiency syndrome (HIV/AIDS)
TWI835794B (zh) * 2018-05-14 2024-03-21 美商昂科Ｃ４公司 抗cd24組合物及其用途
EP3801773A4 (en) * 2018-06-04 2022-03-16 Oncoimmune, Inc. METHOD OF USE OF CD24 FOR PREVENTION AND TREATMENT OF GRAFT VERSUS HOST DISEASE AND MUCOSITIS
EP4017508A1 (en) * 2019-08-23 2022-06-29 Sana Biotechnology, Inc. Cd24 expressing cells and uses thereof
CN112480237B (zh) * 2019-09-12 2023-10-17 上海津曼特生物科技有限公司 一种融合蛋白及其制备方法和应用
US20250195673A1 (en) * 2020-11-30 2025-06-19 Fred Hutchinson Cancer Center Compositions and methods for selective depletion of target molecules
EP4408862A4 (en) * 2021-09-28 2025-11-12 Acroimmune Guangzhou Biotech Ltd Fusion proteins including the O71 core peptide and their use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5798448A (en) * 1994-10-27 1998-08-25 Genentech, Inc. AL-1 neurotrophic factor antibodies
CN101254302B (zh) * 1999-05-07 2011-05-11 杰南技术公司 使用与b细胞表面标志结合的拮抗剂治疗自身免疫病
AU2001259792B2 (en) * 2000-03-29 2005-12-22 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive T cells
US20030106084A1 (en) * 2000-03-29 2003-06-05 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
US20030095966A1 (en) * 2000-03-29 2003-05-22 Yang Liu Method of blocking tissue destruction by autoreactive T cells
HUP0303171A2 (hu) * 2001-02-19 2003-12-29 Merck Patent Gmbh Csökkentett immunogenitású mesterséges fehérjék
US20050214290A1 (en) * 2001-03-29 2005-09-29 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
CA2453406A1 (en) * 2001-07-13 2003-01-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Methods for reducing immunogenicity of polypeptides
CA2505601C (en) * 2002-11-15 2014-10-28 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
AU2007242919B8 (en) * 2003-04-09 2011-11-10 F. Hoffmann-La Roche Ag Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
NZ587776A (en) * 2003-04-09 2012-03-30 Genentech Inc Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor using anti-CD20 antibody
EP1706507A4 (en) * 2003-11-26 2008-02-20 Univ Ohio State Res Found THE RISK AND PROGRESSION OF MULTIPLE SCLEROSIS PREDICTING POLYMORPHS CD24 GENOTYPES
JP2008507591A (ja) * 2004-05-21 2008-03-13 ゼンコー・インコーポレイテッド 免疫原性が改変されたＣ１ｑファミリーメンバータンパク質
US20060160220A1 (en) * 2004-11-12 2006-07-20 Iogenetics Retroviral vectors with introns

Also Published As

Publication number Publication date
PL3260128T3 (pl) 2021-02-08
CA2795823A1 (en) 2011-11-10
DK2563385T3 (da) 2017-11-06
US8808697B2 (en) 2014-08-19
CN105381451B (zh) 2021-03-09
NZ603196A (en) 2014-07-25
EP2563385B1 (en) 2017-08-02
HK1222554A1 (zh) 2017-07-07
HK1176007A1 (zh) 2013-07-19
WO2011139820A1 (en) 2011-11-10
JP6888221B2 (ja) 2021-06-16
JP2015187162A (ja) 2015-10-29
CN105381451A (zh) 2016-03-09
CA2795823C (en) 2019-06-04
EP3260128A1 (en) 2017-12-27
ES2826445T3 (es) 2021-05-18
JP5899206B2 (ja) 2016-04-06
JP2017057216A (ja) 2017-03-23
PT2563385T (pt) 2017-11-10
EA036805B8 (ru) 2021-02-25
KR20130086126A (ko) 2013-07-31
PL2563385T3 (pl) 2018-04-30
IL222739A0 (en) 2012-12-31
JP2019151655A (ja) 2019-09-12
SG184907A1 (en) 2012-11-29
EP2563385A4 (en) 2013-10-02
CN102869369B (zh) 2016-05-18
EP3845238A1 (en) 2021-07-07
EA036805B1 (ru) 2020-12-23
EA201790538A3 (ru) 2017-11-30
CN102869369A (zh) 2013-01-09
JP2018127493A (ja) 2018-08-16
AU2011248540B2 (en) 2014-11-20
ES2645262T3 (es) 2017-12-04
PT3260128T (pt) 2020-10-22
EA027735B1 (ru) 2017-08-31
EP2563385A1 (en) 2013-03-06
WO2011139820A8 (en) 2013-02-07
JP6062502B2 (ja) 2017-01-18
JP6526872B2 (ja) 2019-06-05
EA201790538A2 (ru) 2017-07-31
EA201290961A1 (ru) 2013-04-30
JP2013527168A (ja) 2013-06-27
US20130136739A1 (en) 2013-05-30
EP3260128B1 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
BR112013008959A2 (cg-RX-API-DMAC7.html)
BR112012030039A2 (cg-RX-API-DMAC7.html)
BR112012019354A2 (cg-RX-API-DMAC7.html)
BR112012029986A2 (cg-RX-API-DMAC7.html)
BR112012031500A2 (cg-RX-API-DMAC7.html)
BR112012025307A2 (cg-RX-API-DMAC7.html)
BR112012017960A2 (cg-RX-API-DMAC7.html)
BR112012002126A2 (cg-RX-API-DMAC7.html)
BR112013006400A2 (cg-RX-API-DMAC7.html)
BR112012031826A2 (cg-RX-API-DMAC7.html)
BR112012023249A2 (cg-RX-API-DMAC7.html)
BR112012016456A2 (cg-RX-API-DMAC7.html)
BR112012018256A2 (cg-RX-API-DMAC7.html)
BR112012025308A2 (cg-RX-API-DMAC7.html)
BR112013010949A2 (cg-RX-API-DMAC7.html)
BR112012023265A2 (cg-RX-API-DMAC7.html)
BR112013003284A2 (cg-RX-API-DMAC7.html)
NO2563385T3 (cg-RX-API-DMAC7.html)
BR112013002646A2 (cg-RX-API-DMAC7.html)
BR112012022788A2 (cg-RX-API-DMAC7.html)
BR112012016895A2 (cg-RX-API-DMAC7.html)
BR112013006825A2 (cg-RX-API-DMAC7.html)
BR112013007728A2 (cg-RX-API-DMAC7.html)
BR112012030078A2 (cg-RX-API-DMAC7.html)
BR112013007731A2 (cg-RX-API-DMAC7.html)